What question did this study set out to answer?

This research aims to evaluate the effectiveness of secukinumab as additional therapy for patients with giant cell arteritis.

June 5, 2026NEJM Evidence1 citations

View Full Paper

Secukinumab for Giant Cell Arteritis

JSJohn H. StoneHarvard University NVNils VenhoffUniversity of Freiburg FBFrank ButtgereitHumboldt-Universität zu Berlin

Key Points

This research aims to evaluate the effectiveness of secukinumab as additional therapy for patients with giant cell arteritis.
Randomized, double-blind, placebo-controlled trial
Patients assigned to secukinumab (300 mg and 150 mg) or placebo
Primary outcome measured sustained remission at 52 weeks
25.6% of patients on SEC-300 achieved sustained remission vs 16.9% on placebo (P=0.09)
19.4% of patients on SEC-150 achieved sustained remission vs 17.7% on placebo
Adverse events reported in ≥92% of participants across all groups

Abstract

BACKGROUND: Glucocorticoids (GCs) are standard treatment for giant cell arteritis (GCA). Many patients experience relapses or GC-related toxicity. Secukinumab, a fully human monoclonal antibody that selectively inhibits interleukin-17A, is being studied as additional therapy for GCA. METHODS: GCAptAIN was a randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 3 trial. Patients with new-onset or relapsing GCA were initially randomly assigned (2:1) to either 300 mg of secukinumab (SEC-300) or placebo for 52 weeks. After a protocol amendment, patients were randomly assigned (1:1:1) to either SEC-300, 150 mg of secukinumab (SEC-150), or placebo. Patients in the SEC-300 and SEC-150 groups received a 26-week GC taper. Patients in the placebo group received a 52-week GC taper. The primary outcome was the proportion of patients experiencing sustained remission in the SEC-300 versus placebo groups at week 52. Sustained remission in patients in the SEC-150 group versus patients in the placebo group enrolled after the protocol amendment was a secondary outcome. Adverse events (AEs) and serious AEs (SAEs) were assessed. RESULTS: A total of 140 patients in the SEC-300 group, 98 in the SEC-150 group, and 115 in the placebo group (19 patients were enrolled in the placebo group before and 96 after the protocol amendment) were analyzed for efficacy and safety. The proportion of patients achieving sustained remission at week 52 was 25.6% for SEC-300 versus 16.9% for placebo (marginal difference: 8.7 percentage points; 95% confidence interval CI, -1.3 to 18.8; P=0.09) and 19.4% for SEC-150 versus 17.7% for placebo (marginal difference, 1.6 percentage points; 95% CI, -9.2 to 12.4). AEs occurred in 92.9%, 95.9%, and 97.4% of patients in the SEC-300, SEC-150, and placebo groups, respectively. SAEs occurred in 20.0%, 27.6%, and 32.2% of patients in the SEC-300, SEC-150, and placebo groups, respectively. Serious infections occurred in 5.0%, 9.2%, and 6.1% of patients in the SEC-300, SEC-150, and placebo groups, respectively. CONCLUSIONS: Sustained remission at week 52 did not differ significantly between patients with GCA randomly assigned to receive SEC-300 with a 26-week GC taper versus placebo with a 52-week GC taper. (Funded by Novartis Pharma; EudraCT number, 2020-004809-31; ClinicalTrials.gov number, NCT04930094.).

问 AI

Bookmark

View Full Paper

Cite This Study

Stone et al. (Wed,) studied this question.

synapsesocial.com/papers/6a226694763171746d5457ef https://doi.org/https://doi.org/10.1056/evidoa2600112

问 AI

Bookmark

View Full Paper